Dokument: [18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis
| Titel: | [18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=69971 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250624-110639-4 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Peters, Helena A. [Autor] Bärmann, Ben-Niklas [Autor] Novruzov, Emil [Autor] Weiss, Daniel [Autor] Boschheidgen, Matthias [Autor] Ivan, Vivien Lorena [Autor] Liebers, Nora [Autor] Fischer, Johannes C. [Autor] Mamlins, Eduards [Autor] Radujkovic, Aleksandar [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | FDG-PET/CT, Diffuse large B cell lymphoma, CAR-T, Progression-free survival, Overall survival | |||||||
| Beschreibung: | Objectives
The aim of this study is to evaluate the potential of [18F]FDG-PET/CT in terms of prognostic value and treatment monitoring in relapsed / refractory diffuse large B-cell lymphoma (DLBCL)-patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. Material & methods Forty-eight [18F]FDG-PET/CT scans, acquired at pre-defined time points (t0 – t2) of 18 DLBCL-patients (mean age: 60 ± 12 years) treated with CAR-T cell therapy were retrospectively enrolled. Median time of follow-up was ten months (IQR 6–16) following CAR-T cell infusion. SUVmax, sum of the product of diameters (SPD), Deauville score (DS) and Lugano classification (LC) were evaluated. Clinical parameters (age, sex) were obtained. Survival time analyses for progression-free survival (PFS) and overall survival (OS) were calculated, the latter by using the Kaplan-Meier method and Cox regression including a hazard ratio (HR). P values below 0.05 were defined as statistically significant. 95 %-confidence intervals (CI) were calculated. Results Patients with a SUVmax> 9.0 at t0 (median as threshold value) had a significantly shorter PFS (p = 0.04) and OS (p < 0.01). According to LC, a progressive disease (PD) at t1 (p = 0.02) and t2 (p < 0.01) was correlated with a reduced OS. SUVmax > 9.0 at t0 (p = 0.03, HR = 7.0, CI: 1.3–40.5) and DS > 3 at t1 (p = 0.04, HR = 8.2, CI: 1.1–61.3) were associated with an increased risk of a PD. Conclusion SUVmax of [18F]FDG-PET/CT seems to be useful as a prognostic marker in DLBCL-patients undergoing CAR-T cell therapy. Furthermore, scores of clinical established Deauville classification and Lugano response criteria acquired at post-CAR-T [18F]FDG-PET/CT might be an indicator for early therapy failure. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Peters, H. A., Bärmann, B.-N., Novruzov, E., Weiß, D. A., Boschheidgen, M., Ivan, V. L., Liebers, N., Fischer, J., Mamlins, E., Radujkovic, A., Kobbe, G., Kirchner, J. P., Minko, P., Nachtkamp, K., Jäger, P. S., Antke, C., Hauke, F., Dietrich, S., Antoch, G., & Jannusch, K. (2025). [18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis. European Journal of Radiology Open, 14, Article 100663. https://doi.org/10.1016/j.ejro.2025.100663 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 24.06.2025 | |||||||
| Dateien geändert am: | 24.06.2025 |
